Creative Planning Purchases 8,339 Shares of Novavax, Inc. (NASDAQ:NVAX)

Creative Planning increased its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 34.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,482 shares of the biopharmaceutical company’s stock after purchasing an additional 8,339 shares during the period. Creative Planning’s holdings in Novavax were worth $410,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Shah Capital Management increased its stake in Novavax by 19.0% in the 2nd quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock worth $122,322,000 after buying an additional 1,544,263 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in Novavax in the 1st quarter worth $5,406,000. Renaissance Technologies LLC purchased a new stake in Novavax in the 2nd quarter worth $14,055,000. SG Americas Securities LLC increased its stake in Novavax by 940.7% in the 3rd quarter. SG Americas Securities LLC now owns 1,154,276 shares of the biopharmaceutical company’s stock worth $14,579,000 after buying an additional 1,043,363 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Novavax in the 2nd quarter worth $4,592,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on NVAX shares. Jefferies Financial Group cut their price target on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. B. Riley reiterated a “buy” rating and issued a $26.00 price target (up previously from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. increased their price target on Novavax from $8.00 to $9.00 and gave the stock an “underweight” rating in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, Novavax presently has a consensus rating of “Hold” and an average price target of $17.83.

Novavax Trading Up 2.5 %

Shares of NVAX stock opened at $9.18 on Friday. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The stock’s 50-day moving average price is $11.75 and its 200-day moving average price is $12.23. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -3.33 and a beta of 2.10.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.82 by ($0.83). The firm had revenue of $415.50 million during the quarter, compared to analysts’ expectations of $458.57 million. During the same quarter last year, the business earned $0.58 earnings per share. The company’s revenue was down 2.1% on a year-over-year basis. As a group, research analysts predict that Novavax, Inc. will post -0.9 EPS for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.